Background: There is ample evidence to support the safety and efficacy of the topical anticancer cream Curaderm in the treatment of non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid solamargine in the form of BEC, which has been established as a novel antineoplastic agent. BEC is the initials of the inventor of the described technology. It is known that BEC expresses anti-melanoma properties in cell culture and animals. Because of potential metastasis, clinical work with BEC on melanoma was stalled. However, recent studies show that BEC has anti-metastatic properties and this, together with currently better understanding of the mode of anti-cancer actions of BEC , has led to the treatment of a patient who refused to have surgery for her clinically diagnosed stage II melanoma. Treatment: A 67-year woman had a birthmark that developed into a clinically diagnosed stage II melanoma and was treated with topical application of Curaderm twice daily for 7 weeks. Results: The pattern of response of the melanoma to Curaderm therapy was similar to that observed when basal cell carcinoma is treated with Curaderm. The melanoma responded rapidly to the treatment and in 7 weeks the lesion was removed with no demonstrable side effects. The cosmetic end result was very acceptable. Conclusion: The clinical resolution of the melanoma with Curaderm pharmacotherapy conforms to the cell culture and animal observations that solasodine rhamnosides, and thus Curaderm, is very specific and efficacious for the first in man treatment of melanoma, creating the possibility of a simple treatment for melanoma. Further investigations with controlled clinical trials are warranted.
American Cancer Society (2020) Cancer Facts and Figures 2020. American Cancer Society, Atlanta.
Cancer Council Australia Skin Cancer Statistics & Issues (2020) Skin Cancer Incidence and Mortality.
Guy, G.P., Ekwueme, D.U., Tangka, F.K. and Richardson, L.C. (2012) Melanoma Treatment Costs. A Systematic Review of the Literature, 1990-2011. American Journal of Preventive Medicine, 43, 537-545. https://doi.org/10.1016/j.amepre.2012.07.031
Doran, C.M., et al. (2015) Estimating the Economic Costs of Skin Cancer in New South Wales, Australia. BMC Public Health, 15, Article No. 952. https://doi.org/10.1186/s12889-015-2267-3
Cham, B.E. and Wilson, L. (1987) HPLC of Glycoalkaloids from Solanum sodomaeum. Planta Medica, 1, 59-62. https://doi.org/10.1055/s-2006-962621
Daunter, B. and Cham, B.E. (1990) Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells. Cancer Letters, 55, 209-220. https://doi.org/10.1016/0304-3835(90)90121-D
Cham, B.E., Gilliver, M. and Wilson, L. (1987) Antitumour Effects of Glycoalkaloids Isolated from Solanum sodomaeum. Planta Medica, 1, 34-36. https://doi.org/10.1055/s-2006-962612
Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man. Cancer Letters, 36, 111-118. https://doi.org/10.1016/0304-3835(87)90081-4
Cham, B.E., Daunter, B. and Evans, R. (1991) Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides. Cancer Letters, 59, 183-192. https://doi.org/10.1016/0304-3835(91)90140-D
Punjabi, S., Cook, I., Kersey, P., Marks, R., Finlay, A., Sharpe, G. and Cerio, R. (2000) A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma. The Journal of the European Academy of Dermatology and Venereology, 14, 47-60.
Batsev, A.F., Dobrokhotova, V.Z. and Cham, B.E. (2016) Topical Cream Curadermbec5 Treats a Recalcitrant Basal Cell Carcinoma. Clinical Medical Reviews and Case Reports, 3, 098. https://doi.org/10.23937/2378-3656/1410098
Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s Disease on the Penis with Low Concentrations of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen. Dermatologic Surgery, 37, 858-861. https://doi.org/10.1111/j.1524-4725.2011.02014.x
Cham, B.E. (2020) Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival. Journal of Cancer Therapy, 11, 470-482. https://doi.org/10.4236/jct.2020.118040
Cham, A., Cham, K., Chase, T. and Cham, B. (2015) A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Treatment and Research, 3, 22-27. https://doi.org/10.11648/j.jctr.20150302.12
Cham, B.E. and Daunter, B. (1990) Solasodine Glycosides. Selective Cytotoxicity for Cancer Cells and Inhibition of Cytotoxicity by Rhamnose in Mice with Sarcoma 180. Cancer Letters, 55, 221-225. https://doi.org/10.1016/0304-3835(90)90122-E
Cham, B.E. (2017) Solasodine, Solamargine and Mixtures of Solasodine Rhamnosides: Pathway to Expansive Clinical Anticancer Therapies. International Journal of Clinical Medicine, 8, 692-713. https://doi.org/10.4236/ijcm.2017.812064
Lipscombe, R., Carter, S. and Ruane, M. (2005) Rhamnose Binding Protein. USA Patent No. 6930171.
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal of Biological Sciences, 2, 503-514.
Wang, Y., Gao, J., Gu, G., Li, G., Cui, C., Sun, B., et al. (2011) In Situ RBL Receptor Visualisation and Its Mediated Anticancer Activity for Solasodine Rhamnosides. ChemBioChem, 12, 2418-2420. https://doi.org/10.1002/cbic.201100551
Cham, B.E. (1994) Solasodine Glycosides as Anticancer Agents: Preclinical and Clinical Studies. Asia Pacific Journal of Pharmacology, 9, 113-118.
An, W., Lai, H., Zhang, Y., Liu, M., Lin, X. and Cao, S. (2019) Apoptotic Pathway as the Therapeutic Target for Anticancer Traditional Chinese Medicines. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.00758
Li, X., Zhao, Y., Wu, W.K., Liu, S., Cui, M. and Lou, H. (2011) Solamargine Induces Apoptosis with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U2OS Cells. Life Sciences, 88, 314-321. https://doi.org/10.1016/j.lfs.2010.12.006
Al Sinani, S.S., Eltayeb, E.A., Coomber, B.L. and Adham, S.A. (2016) Solamargine Triggers Cellular Necrosis Selectively in Different Types of Human Melanoma Cancer Cells through Extrinsic Lysosomal Mitochondrial Death Pathways. Cancer Cell International, 16, 287-294. https://doi.org/10.1186/s12935-016-0287-4
Zang, X., Yan, Z., Xu, T., An, Z., Chen, W., Wang, X., Huang, M. and Zhu, F. (2018) SM Derived from Solanum nigrum Induces Apoptosis of Human Cholangio Carcinoma QBC939 Cells. Oncology Letters, 15, 6329-6335. https://doi.org/10.3892/ol.2018.8171
Al Sinani, S.S.S. and Eltayeb, E.A. (2017) The Steroidal Glycoalkaloids Solamargine and Solasonine in Solanum Plants. South African Journal of Botany, 112, 253-269. https://doi.org/10.1016/j.sajb.2017.06.002
Kalalinia, F. and Korimi-Sani, I. (2017) Anticancer Properties of Solamargine: A Systematic Review. Phytotherapy Research, 31, 858-870. https://doi.org/10.1002/ptr.5809
Sani, I.K., Marashi, S.H. and Kalalinia, F. (2015) Solamargine Inhibits Migration and Invasion of Human Hepatocellular Carcinoma Cells through Down-Regulation of Matrix Metalloproteinases 2 and 9 Expression and Activity. Toxicology in Vitro, 29, 893-900. https://doi.org/10.1016/j.tiv.2015.03.012
Li, X., Zhao, Y., Liu, S., Cui, M. and Lou, H. (2011) Induction of Actin Disruption and Downregulation of P-Glycoprotein Expression of Solamargine in Multidrug-Resistant K562/A02 Cells. Chinese Medical Journal, 124, 2038-2044.
Cham, B.E. (2013) Drug Therapy: Solamargine and Other Solasodine Rhamnosyl Glycosides as Anticancer Agents. Modern Chemotherapy, 2, 33-49. https://doi.org/10.4236/mc.2013.22005
Cham, B.E. (2013) Inspired by Nature, Proven by Science. The New Generation Cancer Treatment That Causes Cancer Cells to Commit Suicide. Colorite Graphics, Book, 264 p.
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal of Biological Sciences, 2, 503-514.
Cham, B.E. and Daunter, B. (1990) Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells. Cancer Letters, 55, 209-220. https://doi.org/10.1016/0304-3835(90)90121-D
Wu, Y.H., Chiu, W.T., Young, M.J., Chang, T.H., Huang, Y.F. and Chou, C.Y. (2015) Solanum Incanum Extract Down Regulates Aldehyde Dehydrogenase 1-Medicated Stemness and Inhibits Tumor Formation in Ovarian Cancer Cells. Journal of Cancer, 6, 1011-1019. https://doi.org/10.7150/jca.12738
Cham, B.E. and Daunter, B. (1990) Topical Treatment of Pre-Malignant and Malignant Skin Cancers with Curaderm. Drugs of Today, 26, 55-58.
Yu, S., Sheu, H.M. and Lee, C.H. (2017) Solanum Incanum Extract (SR-T100) Induces Melanoma Cell Apoptosis and Inhibits Established Lung Metastasis. Oncotarget, 8, 103509-103517. https://doi.org/10.18632/oncotarget.21508
Wu, J., Tang, X., Ma, C., Shi, Y., Wu, W. and Hann, S. (2020) The Regulation and Interaction of Colon Cancer-Associated Transcript-1 and miR7-5p Contribute to the Inhibition of SP1 Expression by Solamargine in Human Nasopharyngeal Carcinoma Cells. Phytotherapy Research, 34, 201-213. https://doi.org/10.1002/ptr.6555
Ning, P.H. (2016) Evaluation of Solamargine as a Therapeutic in Bladder Cancer. Scholar Bank@NUS Repository.
Cham, B.E. (2008) Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides. Research Journal of Biological Sciences, 3, 1008-1017.
Sun, L., Zhao, Y., Li, X., Yuan, H., Cheng, A. and Lou, H. (2010) A Lysosomal-Mitochondrial Death Pathway Is Induced by Solamargine in Human K562 Leukemia Cells. Toxicology in Vitro, 24, 1504-1511. https://doi.org/10.1016/j.tiv.2010.07.013
Xiang, S.T., Zhang, Q.H., Tang, Q., Zheng, F., Wu, J.J., Yang, L.J. and Hann, S.S. (2016) Activation of AMPKalpha Mediates Additive Effects of Solamargine and Metformin on Suppressing MUC 1 Expression in Castration-Resistant Prostate Cancer Cells. Scientific Reports, 6, Article No. 36721. https://doi.org/10.1038/srep36721
Kuo, K.W., Hsu, S.H., Li, Y.P., Lin, W.L., Liu, L.F., Chang, L.C., Lin, C.N., Lin, C.C. and Sheu, H.M. (2000) Anticancer Activity Evaluation of the Solanum Glycoalkaloid Solamargine. Triggering Apoptosis in Human Hepatoma Cells. Biochemical Pharmacology, 60, 865-1873. https://doi.org/10.1016/S0006-2952(00)00506-2
Liang, C.H., Liu, L.F., Shiu, L.Y., Huang, Y.S., Chang, L.C. and Kuo, K.W. (2004) Action of Solamargine on TNFs and Cisplatin-Resistant Human Lung Cancer Cells. Biochemical and Biophysical Research Communications, 322, 751-758. https://doi.org/10.1016/j.bbrc.2004.07.183
Xie, X., Zhang, X., Chen, J., Tang, X., Wang, M., Zhang, L., Guo, Z. and Shen, W. (2019) Fe3O4 Solamargine Induces Apoptosis and Inhibits Metastasis of Pancreatic Cancer Cells. International Journal of Oncology, 54, 905-915. https://doi.org/10.3892/ijo.2018.4637
Fu, R., Wang, X., Hu, Y., Du, H., Deng, B., Ao, S., Zhang, L., Sun, Z., Zhang, L., Lv, G. and Ji, J. (2019) Solamargine Inhibits Gastric Cancer Progression by Regulating the Expression of nc NEAT 1-2 via the MAPK Signaling Pathway. International Journal of Oncology, 54, 1545-1554. https://doi.org/10.3892/ijo.2019.4744
Millward, M., Powell, A., Tyson, S., Daly, P., Ferguson, R. and Carter, S. (2005) Phase 1 Trial of Coramsine (SBP002) in Patient with Advanced Solid Tumors. Journal of Clinical Oncology, 23, 3105. https://doi.org/10.1200/jco.2005.23.16_suppl.3105
Munari, C.C., de Oliveira, P.F., Campos, J.C.L., Martins, S.P.L., Da Costa, J.C., Bastos, J.K. and Tavares, D.C. (2014) Antiproliferative Activity of Solanum lycocarpum Alkaloidal Extract and Their Constituents, Solamargine and Solasonine, in Tumor Cell Lines. Journal of Natural Medicines, 68, 236-241. https://doi.org/10.1007/s11418-013-0757-0
Tambuscio, A., Siliprandi, L., Dario, M., Cham, A., Cham, B. and Bordignon, M. (2016) Treatment of Cutaneous Carcinomas with a Topical Cream Containing Solasodine Rhamnosides: Focus on Efficacy, Compliance and Cosmetic Outcomes. European Academy of Dermatology and Venereology Congress, Athens, 19-22 May 2016, p. 0248.
Cham, B.E. (2007) The Eggplant Cancer Cure: A Treatment for Skin Cancers and New Hope for Other Cancers from Nature’s Pharmacy. Smart Publications.
Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers. Research Journal of Biological Sciences, 2, 749-761.
Cham, B.E. (2009) When Does Alternative Become Orthodox? Skin Cancer Treatment with Solasodine Rhamnosyl Glycosides in Its Transitional Stage, a Case Study. Evidence-Based Complementary and Alternative Medicine, 6, 415-420.
Cham, B.E. (2011) Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports. International Journal of Clinical Medicine, 2, 473-477. https://doi.org/10.4236/ijcm.2011.24080
Chase T.R. (2011) CuradermBEC5 for Skin Cancers, Is It? An Overview. Journal of Cancer Therapy, 2, 728-745. https://doi.org/10.4236/jct.2011.25099
Cham, B.E. (2012) Intralesion and CuradermBEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared. International Journal of Clinical Medicine, 3, 115-124. https://doi.org/10.4236/ijcm.2012.32024
Cham, B.E. (2013) Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancer: A Review of Clinical Outcomes. International Journal of Clinical Medicine, 4, 233-238. https://doi.org/10.4236/ijcm.2013.45041
Cham, B.E. (2013) Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with CuradermBEC5. Journal of Cancer Therapy, 4, 588-596. https://doi.org/10.4236/jct.2013.42076
Cham, B.E. (2014) A Review of Solasodine Rhamnosides Therapy for In-Situ Squamous Cell Carcinoma on the Penis. British Journal of Medicine and Medical Research, 4, 621-631. https://doi.org/10.9734/BJMMR/2014/4677
Cham, A. and Cham, B.E. (2015) Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides. International Journal of Clinical Medicine, 6, 326-333. https://doi.org/10.4236/ijcm.2015.65042
Cham, B.E., Cham, K., Cham, A., Chase, T. and Zhou, V. (2015) Treatment of Non Melanoma Skin Cancers: An Intra-Comparison Study of CuradermBEC5 and Various Established Modalities. Journal of Cancer Therapy, 6, 1045-1053. https://doi.org/10.4236/jct.2015.612114
Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008) Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study. International Journal of Dermatology, 47, 78-82. https://doi.org/10.1111/j.1365-4632.2007.03363.x
Bordingnon, M. (2016) Efficacy and Safety of CuradermBEC5 in the Treatment of Basal Cell Carcinoma: A Pilot Study in the Italian Population. European Academy of Dermatology and Venereology Congress, Athens, 19-22 May 2016, p. 0259.
Dobrokhotova, F.Z., Betsev, A.F. and Belysheva, T.S. (2016) The Use of Kuraderm Drug in the Treatment of Basal Cell Carcinoma of the Head and Neck. Head and Neck Tumors, 6, 22-26. https://doi.org/10.17650/2222-1468-2016-6-3-22-26
Xie, X., Zhu, H., Zang, J., Wang, M., Zhu, L., Guo, Z., Shen, W. and Wang, D. (2017) Solamargine Inhibits the Migration and Invasion of HepG 2 Cells by Blocking Epithelial-to-Mesenchymal Transition. Oncology Letters, 14, 447-452. https://doi.org/10.3892/ol.2017.6147
Swetter, S.M., Tsao, H., Bichakjian, C.K., et al. (2019) Guidelines of Care for the Management of Primary Cutaneous Melanoma. JAAD, 80, 208-250. https://doi.org/10.1016/j.jaad.2018.08.055
Chase, T., Cham, K.E. and Cham, B.E. (2020) Evaluation of Dermal Irritation and Skin Sensitization by Curaderm. International Journal of Clinical Medicine, 11, 548-558. https://doi.org/10.4236/ijcm.2020.119047
Chase, T., Cham, K.E. and Cham, B.E. (2020) Curaderm the Long-Awaited Breakthrough for Basal Cell Carcinoma. Vol. 11.